解决复发性/耐药性多发性骨髓瘤的未满足需求:关于当前挑战和新兴疗法的意大利德尔菲共识
Michele Cavo1, Sara Bringhen2, Gabriele Buda3
1Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Frontiers in oncology
|March 2, 2026
概括
管理复发性/耐药性多发性骨髓瘤是具有挑战性的,特别是对于双重耐药性患者. 专家的共识强调了尚未满足的需求以及免疫疗法在意大利改善治疗结果的潜力.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床实践 临床实践
背景情况:
- 复发性或耐火性多发性骨髓瘤带来了重大管理挑战.
- 对莱纳利多米德和达拉图穆马布等新药的耐药性增加限制了治疗选择.
- 双重耐药病例的增加强调了基于证据的治疗指导的急需.
研究的目的:
- 建立专家的共识,在意大利多发性骨髓瘤管理当前的挑战.
- 确定新兴疗法,解决意大利临床领域未得到满足的需求.
- 评估创新免疫疗法的潜在影响.
主要方法:
- 一个经过修改的Delphi过程,涉及一个意见领袖和八名专家.
- 两轮在线调查,随后进行虚拟共识会议.
- 在流行病学,治疗模式和复发性/耐药性多发性髓瘤的未满足需求方面达成共识.
主要成果:
- 在意大利关于多发性骨髓瘤的陈述上达到了90%的共识.
- 专家证实,目前的二线和三线疗法的有效性和安全性有限.
- 存在大量未满足的临床需求,特别是在双重耐药患者中.
结论:
- 对所有复发性/耐药性多发性骨髓瘤患者的有效治疗仍然是一个主要的未满足需求.
- 免疫疗法由于其独特的作用机制,具有很大的潜力来弥补治疗缺口.
- 预计创新的免疫疗法将改善意大利的临床结果.
关键词:
德尔菲的共识 德尔菲的共识贝兰塔马布 (Belantamab) 是一种Mafodotin类药物.这样一来,Ciltacabtagene的自动解读就变成了Ciltacabtagene.达拉图穆马布-耐火剂 达拉图穆马布这是一种耐火的lenalidomide.复发性/耐药性多发性髓瘤没有满足的治疗需求.更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.9K
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
13.6K
相关概念视频
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Drug Therapy
331
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
331
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Therapeutic Drug Monitoring: Affecting Factors
288
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
288
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)